Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
But with Brukinsa and degraders looming, will fixed dosing make the difference?
Enzomenib might be the most promising agent so far, on a cross-trial basis.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
